Elgendy et al. demonstrated that metformin treatment combined with hypoglycemia can significantly inhibit tumor growth by modulating the PP2A/GSK3b/MCL-1 axis.41 Their findings revealed a mechanism through which cancer cells can escape the effects of metformin treatment. Here, MCL1 is linked to cancer.